Kintara Therapeutics (KTRA) has shared an announcement.
TuHURA Biosciences has made waves in the medical community with their announcement that their Phase 1b clinical trial results for the innovative cancer vaccine IFx-2.0 will be presented at the prestigious American Society of Clinical Oncology Annual Meeting. Alongside this, TuHURA is in the spotlight for a proposed merger with Kintara Therapeutics, a move that has the financial markets abuzz. Investors are encouraged to stay informed through official SEC filings and the companies’ communications as the merger process unfolds, highlighting the significance of this development in the biotech and investment sectors.
For detailed information about KTRA stock, go to TipRanks’ Stock Analysis page.
